In another study, Boland et al. compared the effects of cotadutide (a dual GLP-1/GCG receptor agonist), liraglutide, and obeticholic acid in two mouse models of NAFLD [amylin liver NASH (AMLN) diet mice and AMLN diet ob/ob mice] to show that cotadutide outperformed other treatments in improving major histological endpoints, i.e., hepatic steatosis, inflammation, NAS, and fibrosis. This evidence concerns the gene GCG and fatty liver disease.